Page last updated: 2024-12-08

fusidic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

terephthalylidene dicamphor sulfonic acid: structure given in first source; abreviated as TDSA; FDA approved 2006 as component of Anthelios SX along with avobenzone and octocrylene [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID146382
CHEMBL ID3989850
CHEBI ID135830
MeSH IDM0008910
PubMed CID3000226
CHEMBL ID374975
CHEBI ID29013
SCHEMBL ID25646
MeSH IDM0008910

Synonyms (139)

Synonym
mexoryl sx
ecamsule
terephthalylidene dicamphor sulfonic acid
CHEBI:135830
bicyclo(2.2.1)heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxo-
unii-m94r1pm439
(e-e )-3,3'-(1,4-phenylenedimethylidene)bis(2-oxobornane-10-sulfonic acid)
bicyclo(2.2.1)heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxo-, (1s-(1alpha(1r*,4r*),4beta))-
hsdb 8476
ec 410-960-6
ecamsule [usan:usp:inn]
m94r1pm439 ,
(+-)-(3e,3'e)-(p-phenylenedimethylidyne)bis(2-oxo-10-bornanesulfonic acid)
(+-)-(3e,3'e)-3,3'-(p-phenylenedimethylidyne)bis(2-oxo-10-bornanesulfonic acid)
3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid)
nsc 760054
nsc-760054
90457-82-2
mexoryl
HEAHZSUCFKFERC-UHFFFAOYSA-N
terephthalylidenedicamphor sulphonic acid
terephthalylidenedicamphorsulfonic acid
terephthalylidenedicamphorsulphonic acid
BCP16962
[3-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
CHEMBL3989850
[(3e)-3-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
[(3e)-3-[[4-[(e)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid
MLS002207094
(2z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-
29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid, 3alpha,11alpha,16beta-trihydroxy-, 16-acetate, (z)-
3alpha,11alpha,16beta-trihydroxy-29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic acid 16-acetate
nsc 56192
acido fusidico [inn-spanish]
fusidic acid [usan:inn:ban]
fucithalmic
acidum fusidicum [inn-latin]
einecs 230-256-0
c.a.s. 62,602; diethanolamine fusidate
acide fusidique [inn-french]
c.a.s. 62,602
fusidine
nsc56192
3.alpha.,16.beta.-trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
ramycin
sq 16603
fucidic acid
nsc-56192
29-nordammara-17(20), 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)-
fucidin acid
29-nor-8.alpha.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid, 3.alpha.,11.alpha.,16.beta.-trihydroxy-, 16-acetate, (z)-
acid, fusidic
D04281
fusidic acid (usan/inn)
PRESTWICK2_000390
MLS001332649 ,
smr000857101
MLS001332650
sq 16,603
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3a,4a,8a,9b,11a,13a,14b,16b,17z)-
16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic acid
C06694
6990-06-3
DB02703
1QCA
fucidate
CHEBI:29013 ,
(2z)-2-[(17z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid
(-)-fusidic acid
(-)-16beta-acetoxy-3alpha,11alpha-dihydroxyfusida-17(20)z,24-diene-21-oic acid
LMPR0106040001
cem-102
taksta
anhydrous fusidic acid
CHEMBL374975
sq-16603
AKOS005146257
(2e)-2-[(3r,4s,5s,8s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
acide fusidique
acido fusidico
acidum fusidicum
HMS2235B11
S3971
fusidinic acid
59xe10c19c ,
unii-59xe10c19c
flucidin
fusidic acid [ep monograph]
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)
fusidic acid [mi]
fusidic acid [usan]
fusidic acid [who-dd]
fusidic acid [inn]
fusidic acid [ep impurity]
IECPWNUMDGFDKC-MZJAQBGESA-N
SCHEMBL25646
Q-201141
bdbm58924
cid_3000226
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-4,8,10,14-tetramethyl-3,11-bis(oxidanyl)-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic acid
(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-5-heptenoic acid
F1007
mfcd00865135
DTXSID0023086 ,
fusidic acid, european pharmacopoeia (ep) reference standard
fusidic acid for peak identification, european pharmacopoeia (ep) reference standard
NCGC00485232-01
(z)-2-((3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyldodecahydro-1h-cyclopenta[a]phenanthren-17(2h,10h,14h)-ylidene)-6-methylhept-5-enoic acid
(2z)-2-[(3beta,4beta,5alpha,8alpha,9beta,11beta,13alpha,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid
EX-A3797
DS-3261
fusidicacid
Q259930
(3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic-acid
CCG-269829
gtpl10815
cem102
HY-B1350
CS-0013095
(3alpha,4alpha,8alpha,9beta,11alpha,13alpha,147beta,167beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid
fusidic acid for peak identification
EN300-22411576
2-[(1z,2s,3as,3bs,5as,6s,7r,9as,9bs,10r,11ar)-2-(acetyloxy)-7,10-dihydroxy-3a,3b,6,9a-tetramethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-1-ylidene]-6-methylhept-5-enoic acid
acido fusidico (inn-spanish)
acide fusidique (inn-french)
d06ax01
fusidic acid (ep impurity)
fusidic acid (ep monograph)
s01aa13
j01xc01
29-nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)
dtxcid103086
acidum fusidicum (inn-latin)
(2z)-2-((17z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene)-6-methylhept-5-enoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic side effects of certain antimicrobial agents are probably related to their membrane damaging properties."( Cultured human fibroblasts as a model for evaluation of potential in vivo toxicity of membrane damaging antibiotics.
Möllby, R; Thelestam, M, 1980
)
0.26
" CEM-102 was safe and generally well tolerated at all single, multiple, and loading doses administered."( Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.
Clark, K; Degenhardt, TP; Fernandes, P; Gutierrez, MJ; Scott, D; Still, JG, 2011
)
0.37
" Non-US labeling reflects safety concerns related to gastrointestinal, allergic, hematologic, and neurologic adverse events."( The safety record of fusidic acid in non-US markets: a focus on skin infections.
Burnstead, BW; Kraus, CN, 2011
)
0.37
"Fusidic acid (FA) is an active agent against gram-positive bacteria such as Staphylococcus, it is generally well tolerated and the major adverse effects are mild gastrointestinal discomfort, diarrhea, and headache."( Hepatotoxicity and hematologic complications induced by fusidic acid in a patient with hepatitis B cirrhosis: A case report.
Chen, L; He, ZF; Wang, QQ; Zhang, JP, 2019
)
0.51
" Adverse drug reaction was suspected, and FA was stopped immediately, after 1 day of discontinuation of FA, nose bleeding occurred and the platelet count declined further and reached the lowest value of 4000/μL."( Hepatotoxicity and hematologic complications induced by fusidic acid in a patient with hepatitis B cirrhosis: A case report.
Chen, L; He, ZF; Wang, QQ; Zhang, JP, 2019
)
0.51
"Hematologic adverse effect accompanying with hepatotoxicity may be induced by FA."( Hepatotoxicity and hematologic complications induced by fusidic acid in a patient with hepatitis B cirrhosis: A case report.
Chen, L; He, ZF; Wang, QQ; Zhang, JP, 2019
)
0.51

Pharmacokinetics

The ability of evaluate the efficacy of fusidic acid in animal models of infectious disease is limited by the absence of pharmacokinetic data for the agent in laboratory animals. FA has low exposure in mice due to rapid metabolism to a species-specific metabolite, 3-epifusidics acid.

ExcerptReferenceRelevance
"The ability of evaluate the efficacy of fusidic acid in animal models of infectious disease is limited by the absence of pharmacokinetic data for the agent in laboratory animals."( Pharmacokinetics of fusidic acid in laboratory animals.
Findon, G; Miller, TE; Rowe, LC, 1991
)
0.28
"2 mg/l, respectively, indicating a greater than expected increase in Cmax with increasing dose."( Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers.
Andrews, JM; Greig, MA; MacGowan, AP; Reeves, DS; Wise, R, 1989
)
0.28
" A model-independent method was used for the pharmacokinetic analysis."( Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension.
Bourget, P; Duhamel, JF; Roiron, R; Sørensen, H, 1993
)
0.29
" In haemodialysis patients, mean (range) Cmax values for the first dose were 13."( The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis.
Brown, NM; McMullin, CM; Reeves, DS, 1997
)
0.3
" The dosage algorithm of 500 mg/8 hours was microbiologically satisfactory with Cmin measured on D1 and at steady state constantly greater than the MIC of the main organisms concerned (< to 2 micrograms/ml)."( [Pharmacokinetics of fusidic acid in patients with seriously infected burns].
Bourget, P; Carsin, H; Le Bever, H; Lesne-Hulin, A, 1999
)
0.3
" After oral administration of 500 mg Cmax values range from 14."( Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.
Turnidge, J, 1999
)
0.3
"The pharmacokinetic profiles of fusidic acid and cefepime in heart tissues were assessed in 30 patients undergoing elective valve replacement and cardiopulmonary bypass."( Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis.
Apostolakis, E; Giamarellos-Bourboulis, EJ; Giamarellou, H; Giannitsioti, E; Kanellakopoulou, K; Lolas, C; Tselikos, D, 2008
)
0.35
"The objectives of this analysis were to develop a population pharmacokinetic (PK) model to describe the absorption and disposition of fusidic acid after single and multiple doses and to determine the effect of food on the rate and extent of bioavailability."( Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.
Ambrose, PG; Bhavnani, SM; Bulitta, JB; Clark, K; Fernandes, P; Forrest, A; Okusanya, OO; Still, JG, 2013
)
0.39
" Pharmacokinetic analysis of FA and its 3-ketofusidic acid metabolite as well as novel C-3 alkyl ester prodrugs of FA revealed that FA has low exposure in mice due to rapid metabolism to a species-specific metabolite, 3-epifusidic acid."( Pharmacokinetics and Organ Distribution of C-3 Alkyl Esters as Potential Antimycobacterial Prodrugs of Fusidic Acid.
Chibale, K; Dziwornu, GA; Kaur, G; Okombo, J; Strydom, N; Wiesner, L, 2020
)
0.56

Compound-Compound Interactions

The activity of fusidic acid alone and in combination with gentamicin, oxacillin, rifampicin, fosfomycin and ciprofloxacin was investigated against 36 strains of Staphylococcus aureus. Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in conjunction with meropenem, tigecycline, imipenem and sulbactam.

ExcerptReferenceRelevance
"The bactericidal activities of teicoplanin and vancomycin, as single agents or combined with fosfomycin, fusidic acid or rifampicin, were investigated in an in vitro study involving 20 strains of Staphylococcus epidermidis isolated from infected vein catheters."( Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
Simon, M; Simon, VC, 1990
)
0.28
"Killing kinetic experiments were performed with ciprofloxacin, fusidic acid and rifampicin alone and with ciprofloxacin combined with either fusidic acid or rifampicin against ten strains of Staphylococcus aureus."( In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus.
Gutschik, E; Røder, BL, 1989
)
0.28
"In vitro antibacterial activity of fusidic acid (FUC) in combination with cefotaxime (CTX), imipenem (IMP), gentamicin (GEN), amikacin (AKN), rifampin (RIF), fosfomycin (FOS), vancomycin, pefloxacin (PEF) was studied against 19 presumably pathogen meti-R Staphylococcus epidermidis strains."( [In vitro activity of fusidic acid in combination with various antibiotics against Staphylococcus epidermidis].
Appert, A; Delpech, D; Fosse, T; Laffont, C, 1988
)
0.27
"189 bacterial strains were investigated for their in vitro sensitivity against ceftazidime (alone and in combination with another antibiotic)."( In vitro activity of ceftazidime in combination with other antibiotics.
Littschwager, G; Simon, C,
)
0.13
" cerevisiae cells when combined with a nonpolyene antibiotic, fusidic acid or bleomycin A2."( Classification of polyene antibiotics according to their synergistic effect in combination with bleomycin A2 or fusidic acid.
Akiyama, S; Kaneko, M; Komiyama, S; Kuwano, M; Tabuki, T, 1980
)
0.26
"The activity of fusidic acid alone and in combination with gentamicin, oxacillin, rifampicin, fosfomycin and ciprofloxacin was investigated against 36 strains of Staphylococcus aureus."( In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus.
Caillon, J; Drugeon, HB; Juvin, ME, 1994
)
0.29
"The usefulness of fusidic acid, alone or combined with vancomycin, was investigated for the therapy of experimental endocarditis caused in rabbits by a methicillin-resistant strain of Staphylococcus aureus."( Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Carbon, C; Duval, J; Fantin, B; Leclercq, R, 1993
)
0.29
"Recombinant human GH (hGH) combined with a permeation enhancer for the nasal mucosa, sodium tauro-24,25-dihydrofusidate (STDHF), was administered intranasally (in) in six patients with classical GH deficiency."( Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
Albertsson-Wikland, K; Diczfalusy, M; Flyg, C; Hedin, L; Olsson, B; Petersson, AS; Rosberg, S, 1993
)
0.29
"The action of two glycopeptides (vancomycin and teicoplanin) alone or in combination with amikacin or fusidic acid has been studied against 10 non-repetitive strains of methicillin-resistant Staphylococcus."( Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
Barbiery, P; Courcol, RJ; Roussel-Delvallez, M; Wallet, F, 1997
)
0.3
"The effect of rifampicin in combination with dicloxacillin or fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus in human neutrophil granulocytes in the presence of serum was studied."( Extracellular and intracellular killing in neutrophil granulocytes of Staphylococcus aureus with rifampicin in combination with dicloxacillin or fusidic acid.
Black, FT; Nielsen, SL, 1999
)
0.3
"The antimicrobial activities of tetracycline, mupirocin, and fusidic acid are tested in combination with Epicatechin Gallate (ECG), and Ethyl Gallate (EG) using 2 Methicillin resistant (MRSA) and 2 Methicillin sensitive (MSSA) strains of Staphylococcus aureus."( In vitro drug interactions of gallates with antibiotics in Staphylococcus Aureus.
Chu Sing Lim, L; Sakharkar, KR; Sakharkar, MK; Soe, WM; Tzer Pin Lin, R, 2010
)
0.36
" Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains."( Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
Cong, Y; Fan, B; Guan, J; Wang, X, 2016
)
0.43
"Fusidic acid (FA), which was approved in the 1960s in many European and Asian countries, has gained renewed interest due to its continued effectiveness against methicillin-resistant Staphylococcus aureus As rhabdomyolysis has been reported upon coadministration of FA with statins, we aimed to elucidate the underlying molecular mechanisms that contribute to FA-statin drug-drug interactions."( Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.
Birmingham, BK; Bulgarelli, JP; Grimm, SW; Gupta, A; Harris, JJ; Lin, J, 2016
)
0.43
" Fusidic acid (FA) has been used for decades for bone infection, including prosthetic joint infection (PJI), often in combination with rifampin (RIF)."( A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction.
Berkowitz, R; Darouiche, R; Fernandes, P; Iglesias-Ussel, MD; Keedy, K; Kreuzer, S; MacLauchlin, C; Mould, DR; Oldach, D; Pushkin, R, 2016
)
0.43
" The sponsor elected to terminate this study due to a clearly illustrated drug-drug interaction between FA and RIF, which lowered FA levels to a degree that could influence subject outcomes."( A Randomized Study Evaluating Oral Fusidic Acid (CEM-102) in Combination With Oral Rifampin Compared With Standard-of-Care Antibiotics for Treatment of Prosthetic Joint Infections: A Newly Identified Drug-Drug Interaction.
Berkowitz, R; Darouiche, R; Fernandes, P; Iglesias-Ussel, MD; Keedy, K; Kreuzer, S; MacLauchlin, C; Mould, DR; Oldach, D; Pushkin, R, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"Nasal sprays containing different concentrations of the somatostatin analogue octreotide and sodium tauro-24,25-dihydrofusidate (STDHF) as an absorption promoter were evaluated in two consecutive pharmacokinetic studies in healthy volunteers to characterize their bioavailability and local tolerability."( Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.
Bantle, S; Beglinger, C; Drewe, J; Kissel, T; Rummelt, A, 1992
)
0.28
" Sodium fusidate was poorly absorbed after oral administration to rats, although limited absorption occurred in guinea pigs, mice, and rabbits."( Pharmacokinetics of fusidic acid in laboratory animals.
Findon, G; Miller, TE; Rowe, LC, 1991
)
0.28
" Serum and fat levels obtained at the time of surgery show that the antibiotic is well absorbed and penetrates relatively ischaemic tissues."( A study of fucidin uptake in ischaemic tissues.
Antrum, RM; Kendall, SW; Kester, RC; Ramsden, CH, 1988
)
0.27
" Compared with intravenous administration, the mean bioavailability of intranasal insulin was 16."( Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.
Carey, MC; Dubovi, EJ; Flier, JS; Longenecker, JP; Moses, AC; Silver, RD, 1987
)
0.27
" In contrast, the oral bioavailability of the suspension (Fapprox."( Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension.
Bourget, P; Duhamel, JF; Roiron, R; Sørensen, H, 1993
)
0.29
" Bioavailability for the new film-coated tablet is approximately 91% while that of the suspension formulation appears to be much lower."( Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.
Turnidge, J, 1999
)
0.3
" The bioavailability of an antibacterial agent depends on the target bacterial species, the site of infection and the integrity of the haemato-aqueous barrier."( Comparative review of topical ophthalmic antibacterial preparations.
Adenis, JP; Robert, PY, 2001
)
0.31
" As fusidin has previously been claimed to be poorly absorbed in rats after oral administration we wanted to measure the activity of the drug in various organs."( Antidiabetogenic effect of fusidic acid in diabetes prone BB rats: a sex-dependent organ accumulation of the drug is seen.
Buschard, K; Hageman, I, 2002
)
0.31
" In order to improve the absorption rate of insulin into systemic circulations, the effects of pH and absorption enhancers were studied with rabbit eyes."( Alternative delivery of insulin via eye drops.
Chiou, GC; McClellan, DA; Moore, R; Xuan, B, 2005
)
0.33
" Prosthesis retention, in conjunction with debridement and prolonged (for at least 3 months) oral antibiotic therapy, can be an alternative for early postoperative or late acute haematogenous infections, when the duration of symptoms is less than 1 month, the implant is stable, and the pathogen is relatively avirulent and sensitive to an orally well absorbed antibiotic."( Management of infections of osteoarticular prosthesis.
Barberán, J, 2006
)
0.33
"Fusidic acid (CEM-102), an orally bioavailable fusidane antibiotic with a unique mode of action, is under development for treatment of acute gram-positive bacterial skin and skin structure infections, including those caused by methicillin-susceptible and methicillin-resistant Staphylococcus aureus and streptococci."( A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.
Clark, K; Corey, GR; Craft, JC; Das, A; Degenhardt, TP; Fernandes, P; Moriarty, SR; Scott, D; Still, JG, 2011
)
0.37
" Food decreased the extent of bioavailability by 18%."( Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.
Ambrose, PG; Bhavnani, SM; Bulitta, JB; Clark, K; Fernandes, P; Forrest, A; Okusanya, OO; Still, JG, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Oral fusidic acid (tablets dosed at 250 mg twice daily, or a suspension for paediatric use at 20 mg/kg/day given as two daily doses) has shown good efficacy and tolerability. Reports of resistance have led to combination use o.

ExcerptRelevanceReference
" This induction occurred rapidly and probably did not depend on gene dosage effects."( Mechanisms of resistance to fusidic acid in Staphylococcus aureus.
Chopra, I, 1976
)
0.26
" drug abusers on levomethadon maintenance programs, adjustment of the levomethadon dosage may be necessary when specific therapy for HIV infection and associated diseases requires the use of drugs known to be potent inducers of the liver microsomal enzyme system."( Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients.
Brockmeyer, NH; Goos, M; Mertins, L, 1991
)
0.28
" Dosage had no effect on parameters of renal, hepatic or haemopoietic function but 25% of the volunteers complained of upper gastro-intestinal symptoms mainly at the highest dose studied."( Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers.
Andrews, JM; Greig, MA; MacGowan, AP; Reeves, DS; Wise, R, 1989
)
0.28
" Sodium fusidate and erythromycin at the recommended dosage of 30 mg/kg/d for 3 weeks was found to be an effective first-line antibiotic regimen."( Acute osteomyelitis and septic arthritis in children. A simple approach to treatment.
Dall, G; Learmonth, ID; Pollock, DJ, 1984
)
0.27
"A new High-performance liquid chromatographic (HPLC) method for the assay of sodium fusidate (I) or fusidic acid in dosage forms was developed and compared to a microbiological assay."( Determination of sodium fusidate and fusidic acid in dosage forms by high-performance liquid chromatography and a microbiological method.
El-Hoofy, S; Hikal, AH; Shibl, A, 1982
)
0.26
"The pharmacokinetics of fusidic acid (Fucidine, Leo Laboratories) were studied in 10 children after single oral dosing with 20 mg/kg of a new banana-flavoured paediatric suspension (titrating at 50 mg/ml)."( Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension.
Bourget, P; Duhamel, JF; Roiron, R; Sørensen, H, 1993
)
0.29
"2 micrograms ml-1 in groups I, II, and III, respectively; over a dosage interval, areas under the concentration-time curve were 411."( Pharmacokinetics of intravenous fusidic acid in patients with cholestasis.
Dupeyron, JP; Jehl, F; Monteil, H; Peter, JD; Pottecher, T, 1993
)
0.29
" The in dosing results in a plasma peak of hGH very similar to the physiological endogenous peak."( Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
Albertsson-Wikland, K; Diczfalusy, M; Flyg, C; Hedin, L; Olsson, B; Petersson, AS; Rosberg, S, 1993
)
0.29
" However, the dosage and combinations to be used require further study."( Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases.
Gaya, H; Wilson, AP, 1996
)
0.29
" Seven patients on continuous ambulatory peritoneal dialysis (CAPD) were given the same dosage regimen for seven doses."( The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis.
Brown, NM; McMullin, CM; Reeves, DS, 1997
)
0.3
" A higher dosage of vancomycin associated with fusidic acid was rapidly efficient, and total recovery was achieved."( [Postoperative mediastinitis due to methicillin resistant Staphylococcus epidermidis with low sensitivity to vancomycin].
Durandy, Y; Hulin, S, 1997
)
0.3
" The dosage algorithm of 500 mg/8 hours was microbiologically satisfactory with Cmin measured on D1 and at steady state constantly greater than the MIC of the main organisms concerned (< to 2 micrograms/ml)."( [Pharmacokinetics of fusidic acid in patients with seriously infected burns].
Bourget, P; Carsin, H; Le Bever, H; Lesne-Hulin, A, 1999
)
0.3
" When the amount of EF-2 exceeded that of ribosomes sordarin inhibited the GTPase activity following an inverted bell-shaped dose-response curve, whereas when EF-2 and ribosomes were in equimolar concentrations sordarin yielded a typical sigmoidal dose-dependent inhibition."( Sordarin inhibits fungal protein synthesis by blocking translocation differently to fusidic acid.
Domínguez, JM; Gómez-Lorenzo, MG; Martín, JJ, 1999
)
0.3
" Repeated dosing results in substantial drug accumulation when given 8-hourly, and to a variable extent depending on dose when administered 12-hourly."( Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.
Turnidge, J, 1999
)
0.3
"The clinical and bacteriologic efficacy of fusidic acid viscous drops combined with the convenience of a twice-daily dosage regimen establishes this antibiotic as first-line treatment for suspected acute bacterial conjunctivitis and a favourable alternative to other broad-spectrum antibiotics."( Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
Dattani, D; Jackson, WB; Leeder, RG; Low, DE; MacDougall, R; Whitsitt, PF, 2002
)
0.31
" dosage and for 194 (89."( Fusidic acid suspension twice daily: a new treatment schedule for skin and soft tissue infection in children, with improved tolerability.
Bielsa, I; Iglesias, L; Rutkai, K; Somogyi, T; Török, E, 2004
)
0.32
" Oral fusidic acid (tablets dosed at 250 mg twice daily, or a suspension for paediatric use at 20 mg/kg/day given as two daily doses) has shown good efficacy and tolerability."( Fusidic acid in dermatology: an updated review.
Schöfer, H; Simonsen, L,
)
0.13
"Aerosol is a new dosage form for wound dressing and wound healing."( Mechanical properties and water vapour permeability of film from Haruan (Channa striatus) and fusidic acid spray for wound dressing and wound healing.
Bai, SB; Noor, AM, 2010
)
0.36
" Front-loaded and non-front-loaded fusidic acid dosing regimens were evaluated over 48 h using a 1-compartment infection model and over 240 h using a hollow fiber infection model (HFIM)."( Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.
Ambrose, PG; Bhavnani, SM; Bulik, CC; Bülitta, JB; Fernandes, P; Forrest, A; Okusanya, OO; Tsuji, BT, 2011
)
0.37
"Perhaps the most crucial step in the clinical development of an antimicrobial agent is the selection of a dosing regimen."( Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.
Ambrose, PG; Bhavnani, SM; Bulitta, JB; Fernandez, PB; Forrest, A; Okusanya, OO; Tsuji, BT, 2011
)
0.37
" A new dosing regimen has been patented, allowing FA to be used as monotherapy, and decreased resistance selectivity has been shown."( Efforts to support the development of fusidic acid in the United States.
Fernandes, P; Pereira, D, 2011
)
0.37
" As a result of the autoinhibition of clearance, steady state can be achieved earlier with dosing regimens that contain higher doses (after 8 days for 750 mg q12h and 1 day for 1,500 mg q12h on day 1 followed by 600 mg q12h versus 3 weeks for 500 mg q12h)."( Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.
Ambrose, PG; Bhavnani, SM; Bulitta, JB; Clark, K; Fernandes, P; Forrest, A; Okusanya, OO; Still, JG, 2013
)
0.39
" Reports of resistance have led to combination use of fusidic acid with rifampin, which is superseded by the development of a new dosing regimen for fusidic acid that can be used in monotherapy."( Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.
Fernandes, P, 2016
)
0.43
" There are, however, concerns about the emerging bacterial resistance against topical antibacterial agents such as fusidic acid, due to the prolonged treatment period of its marketed dosage forms."( Preclinical development of sodium fusidate antibiotic cutaneous spray based on water-free lipid formulation system.
Carlsson, A; Håkansson, J; Herslöf, B; Holmbäck, J; Johansson, J; Rinwa, P; Rinwa, V, 2022
)
0.72
" FA and its active metabolite (3-keto FA) were measured in plasma and cerebrospinal fluid (CSF) to assess the treatment of FA, and the results indicated that 1,500 mg per day of FA was sufficient to achieve therapeutic concentrations in both plasma and CSF in intracranial infection patients, while the dosage did not experience unexpected regimen-related toxicity."( Fusidic Acid and Its Major Active Metabolite Penetration into Cerebrospinal Fluid for Assessing Treatment of Intracranial Infections.
Dang, ZL; He, ZF; Lu, N; Rao, Z; Wei, YH; Yang, G; Zhang, YH; Zheng, MH, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
protein synthesis inhibitorA compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
EC 2.7.1.33 (pantothenate kinase) inhibitorAn EC 2.7.1.* (phosphotransferases with an alcohol group as acceptor) inhibitor that interferes with the action of pantothenate kinase (EC 2.7.1.33).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
steroid antibiotic
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
11alpha-hydroxy steroid
sterol esterA steroid ester obtained by formal condensation of the carboxy group of any carboxylic acid with the 3-hydroxy group of a sterol.
steroid acidAny steroid substituted by at least one carboxy group.
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency63.09570.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
Guanine nucleotide-binding protein GHomo sapiens (human)Potency35.48131.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Type Iii Chloramphenicol AcetyltransferaseShigella flexneriKi5.40005.40005.40005.4000AID977610
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)17.40000.40002.75008.6000AID1209456
Bile salt export pumpRattus norvegicus (Norway rat)Ki2.20000.30003.10006.1000AID681728
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.56670.11007.190310.0000AID1209455; AID1443980; AID1473738
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki8.70000.84004.968210.0000AID679020; AID679021; AID679028
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)52.00000.00401.966610.0000AID1873194
large T antigenBetapolyomavirus macacaeIC50 (µMol)20.42000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)0.26950.06008.9128130.5170AID1902; AID1914
AlbuminHomo sapiens (human)Kd12.00000.08933.31358.0000AID557095
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)0.36200.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)0.36200.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (497)

Assay IDTitleYearJournalArticle
AID565818Antimicrobial activity against Neisseria gonorrhoeae isolates up to 2 ug/ml by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID561776Antimicrobial activity against Staphylococcus aureus isolate 27657 expressing FusC by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID324689Antimicrobial activity against Staphylococcus aureus CS9572007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID285348Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20020488 in CCY medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID510748Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID285350Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20040332 in CCY media2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID323834Antibacterial activity against fusidic acid resistant Clostridium difficile 26:3 isolate with fusA M16I and H455N mutation after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID557093Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID285344Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20040332 in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424579Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH340 (SCV-12) harboring Gly617Asp mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424613Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH287 harboring Ala655Glu mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561996Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27971 carrying pUB101 expressing cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID525129Suppression of drug resistance development in Staphylococcus aureus RN4220 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 25 days2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID424343Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH206 harboring Arg464Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID519481Antibacterial activity against Staphylococcus aureus T991 by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1904946Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as reduction in bacterial count in spleen administered 72 hrs post infection topically twice daily for 4 days2022European journal of medicinal chemistry, Apr-15, Volume: 234Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID324711Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pAJ96:SAS0043) (fusC) gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID297186Antibacterial activity against multidrug resistant Staphylococcus aureus 495892007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.
AID584115Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID424574Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH369 (SCV-41) harboring Gln115Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID520086Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID581655Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1532493Cytotoxicity against human KBV cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID285347Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20010734 in CCY medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID279570Antimicrobial activity against Salmonella enterica serovar Typhimurium JB393 in Caenorhabditis elegans2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Caenorhabditis elegans as a model to determine fitness of antibiotic-resistant Salmonella enterica serovar typhimurium.
AID545937Ratio of MIC for Klebsiella pneumoniae ATCC 13883 to MIC for Klebsiella pneumoniae ATCC 13883 in presence of 4 ug/ml of NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID324694Antimicrobial activity against Staphylococcus aureus CS9922007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1230066Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2691 assessed as inhibition of bacterial growth2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID424594Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH349 (SCV-21) harboring -1 frameshift mutation at nucleotide 404 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID261274Antibacterial activity against Staphylococcus aureus CJ 234 R2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID571211Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424581Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH329 (SCV-1) harboring Arg659Cys mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1904945Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as reduction in bacterial count administered 72 hrs post infection topically twice daily for 4 days2022European journal of medicinal chemistry, Apr-15, Volume: 234Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID681728TP_TRANSPORTER: inhibition of Taurocholate uptake in canalicular membrane vesicles of rat liver2002Biochemical pharmacology, Jul-01, Volume: 64, Issue:1
Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID261279Antibacterial activity against Corynebacterium xerosis FF2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424601Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH378 (SCV-50) harboring -1 frameshift mutation at nucleotide 221 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID285341Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20010734 in in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID571394Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561989Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27856 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1532501Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID557115Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 20 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID424829Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH420 harboring deletion of nucleotide 72-80 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323857Antibacterial activity against fusidic acid resistant Clostridium difficile 58:1 isolate with fusA H455Q mutation after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID571390Antibacterial activity against Acinetobacter baumannii F264 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424337Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH194 harboring Pro404Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID373748Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID586056Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID519833Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID324697Antimicrobial activity against Staphylococcus aureus CS8662007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1322511Antibacterial activity against Staphylococcus aureus infected in BALB/c mouse model of superficial skin infection and biofilm formation assessed as reduction in bacterial load in skin at 40 mg/kg applied topically once daily for 4 days and measured 18 hrs
AID565817Antimicrobial activity against Neisseria gonorrhoeae isolates by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID396041Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID571393Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1532513Antibacterial activity against Staphylococcus aureus
AID545935Ratio of MIC for Escherichia coli ATCC 25922 to MIC for Escherichia coli ATCC 25922 in presence of 4 ug/ml of NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID261277Antibacterial activity against Staphylococcus aureus CJ 2882006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID558031Drug concentration in human plasma2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID396037Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID576355Antibacterial activity against fusidic acid-resistant, methicillin-susceptible Staphylococcus aureus after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID519482Antibacterial activity against Staphylococcus aureus T2019 with G2576T mutation in 23S rRNA genes by Etest method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.
AID576377Antibacterial activity against Staphylococcus aureus harboring L461Kb and C473S mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID565820Antimicrobial activity against Chlamydia trachomatis isolates2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID424596Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH358 (SCV-30) harboring -1 frameshift mutation at nucleotide 423 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586046Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID576354Antibacterial activity against fusidic acid-resistant, methicillin-resistant Staphylococcus aureus after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID323852Antibacterial activity against fusidic acid resistant Clostridium difficile 100:2 isolate with fusA V119A mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1415898Antiplasmodial activity against Plasmodium falciparum D10 after 48 hrs2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID424592Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH392 (SCV-64) harboring -1 frameshift mutation at nucleotide 383 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1382508Toxicity in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID576356Antibacterial activity against fusidic acid-resistant methicillin-resistant Staphylococcus aureus harboring P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID520088Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID545933Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 4 ug/ml NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID285162Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID324708Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pCU1:SSP2165) (fusD) gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID576364Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring L461K mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID565480Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID424582Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH331 (SCV-3) harboring Arg659His mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID581668Antibacterial activity against revertant Staphylococcus aureus infected in human THP-1 cells assessed as log reduction of extracellular CFU level after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID323833Antibacterial activity against fusidic acid resistant Clostridium difficile 26:2 isolate with fusA D432N mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID561774Antimicrobial activity against Staphylococcus aureus isolate 27971 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424615Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH297 harboring Ser660Pro mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID571395Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424825Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH292 harboring Gly664Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323850Antibacterial activity against fusidic acid resistant Clostridium difficile 73:2 isolate with fusA I459R mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424607Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH390 (SCV-62) harboring +1 frameshift mutation at nucleotide 84 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1566017Cytotoxicity against human KBV cells assessed as cell survival at 5 uM after 72 hrs by MTT assay relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.
AID510749Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID1532503Cytotoxicity against human KBV cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID576357Antibacterial activity against fusidic acid-resistant methicillin-susceptible Staphylococcus aureus harboring P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324709Antimicrobial activity against Staphylococcus aureus RN4220 expressing pAJ962007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID424832Ratio of MIC for kanamycin-resistant Staphylococcus aureus harboring mutations in FusE gene to MIC for wild type kanamycin-susceptible Staphylococcus aureus AH0012007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561767Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 27962 expressing FusA Met453Ile mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID323838Antibacterial activity against fusidic acid resistant Clostridium difficile 51:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID571429Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID424589Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH370 (SCV-42) harboring TAA stop codon at nucleotide 229 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID581666Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID396040Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID586053Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID424580Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH332 (SCV-4) harboring Ala655Glu mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID285349Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20030203 in CCY media2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID565484Bactericidal activity against methicillin-resistant Staphylococcus aureus after 24 hrs by M26-A method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID576371Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A71V in domain 1 and P404L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID581658Cmax in human plasma2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID581664Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285340Antibacterial activity against Staphylococcus aureus LUG855 in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID557094Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID557117Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 215 to 430 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID561764Antimicrobial activity against Staphylococcus aureus isolate 27731 expressing FusA Ala71Val, Asp189Gly, Pro406Leu mutant and harboring pMW2 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1575939Antimycobacterial activity against Mycobacterium tuberculosis H37RvMA ATCC 27294 cultured in protein-based Middlebrook 7H9 medium supplemented with glucose, albumin-dextrose-catalase and Tween 80 assessed as inhibition of bacterial growth incubated for 7
AID1720195Cytotoxicity against CHOK1 cells assessed as reduction in cell viability2020Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13
Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity.
AID323849Antibacterial activity against fusidic acid resistant Clostridium difficile 73:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID525127Suppression of drug resistance development in recA-deficient Staphylococcus aureus KB103 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 20 days2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID565813Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID285161Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID285351Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20041010 in CCY media2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424597Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH339 (SCV-11) harboring -1 frameshift mutation at nucleotide 144 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576359Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring E444K mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324717Antimicrobial activity against Staphylococcus lugdunensis 164962007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID424590Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH346 (SCV-18) harboring -1 frameshift mutation at nucleotide 238 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324690Antimicrobial activity against Staphylococcus aureus2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID581665Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565502Plasma protein binding in human2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID324707Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pCU1:SAS0043) (fusC) gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID561990Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27971 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1361132Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in BALB/c mouse wound infection model assessed as reduction in bacterial burden in wound at 2% administered topically bid for 5 days relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.
AID424600Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH384 (SCV-56) harboring -1 frameshift mutation at nucleotide 221 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID565814Antimicrobial activity against Neisseria gonorrhoeae assessed as susceptible isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID1532492Cytotoxicity against human HeLa cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID561992Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 28332 carrying pUB101 cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID571213Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID679021TP_TRANSPORTER: inhibition of LTC4 uptake in Mrp2-expressing HEK cells2002Biochemical pharmacology, Jul-01, Volume: 64, Issue:1
Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID285343Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20030203 in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID520085Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID576369Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A67T in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1460343Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID561985Antimicrobial activity against Staphylococcus aureus isolate 28084 expressing FusC and harboring pMW2 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID540930Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor 92G harboring rpsL gene with inserted glycine at position 92 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID525124Suppression of resistance related recombination in Staphylococcus aureus RN4220 at 0.25 times MIC at 42 degC2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID561982Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28400 expressing FusC C90T mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1482267Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID540931Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP1 harboring rpsL A262G and C271T mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID324696Antimicrobial activity against Staphylococcus aureus CS8082007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID355207Cytotoxicity against african green monkey Vero cells after 72 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Antimycobacterial cycloartanes from Borrichia frutescens.
AID561995Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27856 carrying pUB101 expressing cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532505Induction of apoptosis in human HeLa cells assessed as increase in early apoptotic cells at 2 uM after 24 hrs by TUNEL staining based fluorescence microscopic analysis
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID424611Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH288 harboring Gly617Asp mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424583Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH347 (SCV-19) harboring Arg659Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424344Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH190 harboring Arg464His mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1532494Cytotoxicity against human KBV cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID424573Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH366 (SCV-38) harboring Pro114His mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576112Antimicrobial activity against mecA-positive Staphylococcus sciuri harboring staphylococcus aureus mecA gene assessed as resistant isolates2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID1415896Cytotoxicity against CHO cells by MTT assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID565481Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID424584Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH367 (SCV-39) harboring Gly664Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424341Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH197 harboring Leu456Phe mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324712Antimicrobial activity against Staphylococcus aureus RN4220 expressing (pAJ96:SSP2165) (fusD) gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID323856Antibacterial activity against fusidic acid resistant Clostridium difficile 248:3 isolate with fusA H455R mutation after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID324695Antimicrobial activity against Staphylococcus aureus CS7302007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1594381Induction of inflammation in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 4 times daily during compound dosing2019Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9
Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID323835Antibacterial activity against fusidic acid resistant Clostridium difficile 49:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID324716Antimicrobial activity against Staphylococcus lugdunensis 166412007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID324714Antimicrobial activity against Staphylococcus intermedius CL22007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID324704Antimicrobial activity against Staphylococcus aureus CS8602007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID585877Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID557090Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID586052Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID540927Antimicrobial activity against Streptomyces coelicolor 1147 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID520081Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID396034Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID561980Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28150 expressing FusC and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID576360Antibacterial activity against Staphylococcus aureus harboring G451V mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424577Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH336 (SCV-8) harboring His438Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586038Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type U assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID324715Antimicrobial activity against Staphylococcus intermedius NCTC 110482007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID576363Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424345Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH188 harboring Gly664Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586051Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID576374Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring E444V and L461F mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID424340Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH201 harboring Gly452Cys mutation in fusA after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID584114Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID565819Trough plasma concentration in human2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID424567Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH204 harboring deletion of nucleotide 203-231 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586041Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID561768Antimicrobial activity against Staphylococcus aureus isolate 28362 expressing FusA Val90Ile mutant by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID424595Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH374 (SCV-46) harboring -5 frameshift mutation at nucleotide 236-240 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323846Antibacterial activity against fusidic acid resistant Clostridium difficile 63:2 isolate with fusA T434I after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID224494In vitro inhibition of protein synthesis in tobacco mosaic virus mRNA-encoded proteins in rabbit reticulocyte lysate2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Inhibition of protein synthesis by didemnins: cell potency and SAR.
AID540928Antimicrobial activity against streptomycin-resistant Streptomyces coelicolor KO-178 harboring rpsL K88E mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID424576Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH334 (SCV-6) harboring Thr436Ile mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1382507Induction of inflammation in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as swelling around wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID323844Antibacterial activity against fusidic acid resistant Clostridium difficile 62:3 isolate with fusA A375 deletion after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID323848Antibacterial activity against fusidic acid resistant Clostridium difficile 72:2 isolate with fusA S116L and A374V mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1532504Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID540929Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor KO-347 harboring rpsl P91S mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID424608Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH386 (SCV-58) harboring -1 frameshift mutation at nucleotide 90 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323839Antibacterial activity against fusidic acid resistant Clostridium difficile 51:2 isolate with fusA S449P mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424342Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH187 harboring His457Tyr mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586055Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1873194Inhibition of ABCG2 (unknown origin) expressed in dog MDCK-II-BCRP cells incubated for 120 mins by transwell migration assay2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID571209Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID323836Antibacterial activity against fusidic acid resistant Clostridium difficile 49:2 isolate after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424824Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH296 harboring Gly664Ala mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID571212Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 1 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID565485Bactericidal activity against methicillin-susceptible Staphylococcus aureus after 24 hrs by M26-A method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID586054Antimicrobial activity against Staphylococcus aureus clone 4-4 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1532496Cytotoxicity against human U87 cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID557097Protein binding in serum2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID323854Antibacterial activity against fusidic acid resistant Clostridium difficile 107:3 isolate with fusA A459R mutation after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1904944Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in BALB/c mouse assessed as recovery of body weight loss administered 72 hrs post infection topically twice daily for 4 days2022European journal of medicinal chemistry, Apr-15, Volume: 234Exploring the structure-activity relationships of diphenylurea as an antibacterial scaffold active against methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID565491Ratio of MBC to MIC for methicillin-susceptible Staphylococcus aureus in presence of 50% human plasma2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID324699Antimicrobial activity against Staphylococcus aureus CS8512007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID424568Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH209 harboring deletion of nucleotide 404-427 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561777Antimicrobial activity against Staphylococcus aureus isolate 28416 expressing FusC by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424614Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH291 harboring Arg659His mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID584117Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method in presence of efflux pump inhibitor CCCP2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID576367Antibacterial activity against methicillin-susceptible Staphylococcus aureus harboring M651I mutation in domain 5 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID396039Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID324693Antimicrobial activity against Staphylococcus aureus RN4220 expressing pCU1:fusB gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1428626Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method2017European journal of medicinal chemistry, Feb-15, Volume: 127Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
AID576111Antimicrobial activity against mecA-deficient Staphylococcus sciuri harboring staphylococcus aureus mecA gene assessed as resistant isolates2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID581671Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID581670Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID477409Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID1575940Antimycobacterial activity against Mycobacterium tuberculosis H37RvMA ATCC 27294 cultured in non protein-based Middlebrook 7H9 medium supplemented with glucose-casitone-tyloxapol assessed as inhibition of bacterial growth incubated for 7 days in by alamar
AID323845Antibacterial activity against fusidic acid resistant Clostridium difficile 63:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1575942Antimycobacterial activity against Mycobacterium tuberculosis
AID355206Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 days by radiorespirometric assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Antimycobacterial cycloartanes from Borrichia frutescens.
AID424348Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH202 harboring CTG start codon at nucleotide 1 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID424602Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH351 (SCV-23) harboring -4 frameshift mutation at nucleotide 45-48 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561988Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27624 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID424598Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH337 (SCV-9) harboring -1 frameshift mutation at nucleotide 220 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID586049Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1460342Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 by LDH assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID545917Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method in presence of 4 ug/ml NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID679028TP_TRANSPORTER: inhibition of E217betaG uptake in canalicular membrane vesicles of rat liver2002Biochemical pharmacology, Jul-01, Volume: 64, Issue:1
Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID424833Ratio of MIC for kanamycin-resistant Staphylococcus aureus harboring mutations in FusA gene to MIC for wild type kanamycin-susceptible Staphylococcus aureus AH0012007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324719Antimicrobial activity against Staphylococcus lugdunensis 408692007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID557096Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID525128Suppression of drug resistance development in Staphylococcus aureus isolate EMRAS-15 assessed as prolonged length of subculture to develop Linezolid resistance at 4 times MIC and 0.25 times IC50 after 25 days2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.
AID557116Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 160 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID424587Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH377 (SCV-49) harboring +1 frameshift mutation at nucleotide 23 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID576375Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q and L461F mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID571428Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.5 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID519834Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID561993Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 28444 carrying pUB101 expressing cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID679020TP_TRANSPORTER: inhibition of LTC4 uptake in canalicular membrane vesicles of rat liver2002Biochemical pharmacology, Jul-01, Volume: 64, Issue:1
Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate.
AID1266403Competitive inhibition of chloramphenicol acetyl transferase (unknown origin) assessed as binding affinity2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
New Frontiers in Druggability.
AID285160Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID557092Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID323847Antibacterial activity against fusidic acid resistant Clostridium difficile 72:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID323843Antibacterial activity against fusidic acid resistant Clostridium difficile 62:2 isolate after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID261273Antibacterial activity against Staphylococcus aureus CJ 2472006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID576361Antibacterial activity against Staphylococcus aureus harboring M453I mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID557095Binding affinity to first site on human serum albumin by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID324698Antimicrobial activity against Staphylococcus aureus CS6022007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID424609Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible wild type Staphylococcus aureus 8325-4 clinical isolate after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID510750Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID323842Antibacterial activity against fusidic acid resistant Clostridium difficile 62:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID565490Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus in presence of 50% human plasma2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID1460341Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in erythrocytes after 48 hrs by giemsa staining based assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID324703Antimicrobial activity against Staphylococcus aureus CS8052007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID324713Antimicrobial activity against Staphylococcus intermedius CL12007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID324700Antimicrobial activity against Staphylococcus aureus CS9792007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1532500Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID424606Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH330 (SCV-2) harboring -1 frameshift mutation at nucleotide 423 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424612Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH294 harboring Gly628Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424828Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH290 harboring duplication mutation at nucleotide 202-293 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424586Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH352 (SCV-24) harboring -1 frameshift mutation at nucleotide 106 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID571397Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561987Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 28444 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1382502Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 in Balb/c mouse skin infection model assessed as reduction in bacterial burden in wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID424346Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH193 harboring TAA stop codon at nucleotide 299 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID497969Antimicrobial activity against Staphylococcus aureus SJ116172010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.
AID571208Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561772Antimicrobial activity against Staphylococcus aureus isolate 27624 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID586047Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 6 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID576358Antibacterial activity against Staphylococcus aureus harboring P406L mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID585879Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID520082Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID576370Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A70V in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1382506Induction of inflammation in Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 assessed as redness around wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post last dose relative2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID576110Antimicrobial activity against mecA-positive Staphylococcus sciuri assessed as resistant isolates2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID424336Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH207 harboring Thr385Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576109Antimicrobial activity against mecA-deficient Staphylococcus sciuri assessed as resistant isolates2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.
AID424591Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH333 (SCV-5) harboring TAA stop codon at nucleotide 249 in rplF but gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424578Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH338 (SCV-10) harboring Arg464Cys mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID545929Antimicrobial activity against Enterobacter cloacae ATCC 23355 by Etest method in presence of 4 ug/ml NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1594380Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 infected in Balb/c mouse assessed as reduction in bacterial burden in wounded skin area at 2% administered topically twice daily for 5 consecutive days measured 12 hrs post 2019Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9
Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID1460345Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive Plasmodium falciparum NF542017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID424610Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH421 harboring Pro404Arg mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID510747Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID424826Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH298 harboring Gly664Val mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID520083Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID424827Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH422 harboring +2 frameshift mutation at nucleotide 222 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID323858Antibacterial activity against fusidic acid resistant Clostridium difficile 58:2 isolate with fusA H455Q mutation after 8 to 13 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID576376Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q and L461K mutations in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID545925Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by Etest method in presence of 4 ug/ml NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1532498Cytotoxicity against human MKN45 cells assessed as cell viability at 1.5 uM after 72 hrs by MTT assay relative to control
AID565483Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method in presence of 50% human plasma2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID565816Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by EUCAST method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID323841Antibacterial activity against fusidic acid resistant Clostridium difficile 57:3 isolate with fusA S116L and A374V mutation after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424599Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH357 (SCV-29) harboring TAA stop codon at nucleotide 301 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561769Antimicrobial activity against Staphylococcus aureus isolate 28130 expressing FusA Leu461Ser mutant pMW2 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581653Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 5 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID561770Antimicrobial activity against Staphylococcus aureus isolate 28332 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID373750Antimicrobial activity against mupirocin-resistant methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID571396Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID520087Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID323853Antibacterial activity against fusidic acid resistant Clostridium difficile 107:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID373747Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID392208Antibacterial activity against Staphylococcus aureus ATCC 292132009Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.
AID323832Antibacterial activity against fusidic acid resistant Clostridium difficile 26:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424831Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH416 harboring deletion of nucleotide 395-398 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID571389Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.25 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571391Antibacterial activity against Acinetobacter baumannii F264 by Etest method in presence of 0.125 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID561773Antimicrobial activity against Staphylococcus aureus isolate 27856 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581669Antibacterial activity against normal phenotype Staphylococcus aureus in infected in human THP-1 cells assessed as log reduction of extracellular CFU level after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID324701Antimicrobial activity against Staphylococcus aureus CS10832007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID586050Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U8 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID545921Antimicrobial activity against Escherichia coli IH3080 by Etest method in presence of 4 ug/ml NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID561765Antimicrobial activity against Staphylococcus aureus isolate 27844 expressing FusA Ala376Val, Leu461Phe, Asp463Gly, Ala655Pro mutant and harboring pMW2 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1575943Protein binding in human serum
AID424603Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH360 (SCV-32) harboring ATA start codon at nucleotide 3 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561983Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28410 expressing FusC C90T mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID585878Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 2 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID324702Antimicrobial activity against Staphylococcus aureus CS11282007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID586043Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U5 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID285342Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20020488 in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID558030Drug concentration in human brain2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID373749Antimicrobial activity against mupirocin-susceptible methicillin-resistant Staphylococcus aureus assessed as resistant rate by broth microdilution method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
AID396038Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID584116Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP722010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID323855Antibacterial activity against fusidic acid resistant Clostridium difficile 248:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID424605Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH362 (SCV-34) harboring TAA stop codon at nucleotide 282 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576373Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring A376V in domain 2 and L456F mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID261276Antibacterial activity against Staphylococcus aureus CJ 2512006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424572Antibacterial activity against kanamycin-susceptible wild type Staphylococcus aureus AH001 after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID324718Antimicrobial activity against Staphylococcus lugdunensis 314402007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID424335Antibacterial activity against fusidic acid-susceptible wild type Staphylococcus aureus 8325-4 after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576368Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring M16I in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324705Antimicrobial activity against Staphylococcus aureus CS10762007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID565488Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID561775Antimicrobial activity against Staphylococcus aureus isolate 27980 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID586039Antimicrobial activity against Staphylococcus aureus clone 1-1 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1720196Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2020Bioorganic & medicinal chemistry, 07-01, Volume: 28, Issue:13
Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity.
AID561766Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 27768 expressing FusA Leu461Ser mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532495Cytotoxicity against human U87 cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID565489Ratio of MBC to MIC for methicillin-susceptible Staphylococcus aureus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID324691Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 4762007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID561986Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 28332 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID561771Antimicrobial activity against Staphylococcus aureus isolate 28444 expressing FusB and harboring pUB101 carrying cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID581667Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285159Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID510559Antibacterial activity against Escherichia coli AG102MB2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID396036Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID424585Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH380 (SCV-52) harboring -1 frameshift mutation at nucleotide 158 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1532497Cytotoxicity against human MKN45 cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID581654Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285346Antibacterial activity against Staphylococcus aureus LUG855 in CCY media2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID396035Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by standard disk diffusion method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID1289278Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 1 B690208 after 24 hrs2016Journal of natural products, Jan-22, Volume: 79, Issue:1
Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale.
AID581663Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID424575Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH364 (SCV-36) harboring Asp434Asn mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576366Antibacterial activity against methicillin-susceptible Staphylococcus aureus harboring P478S mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID561991Antimicrobial activity against cadXD coding sequence deficient Staphylococcus aureus isolate 27980 expressing FusB by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1594382Toxicity in wounded skin area of Balb/c mouse infected with methicillin-resistant Staphylococcus aureus USA300 at 2% administered topically twice daily for 5 consecutive days measured 4 times daily during compound dosing2019Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9
Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus.
AID323851Antibacterial activity against fusidic acid resistant Clostridium difficile 100:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID565815Antimicrobial activity against Neisseria gonorrhoeae assessed as resistant isolates by CLSI method2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
AID540932Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP2 harboring rpsL K88E mutant gene and inserted glycine at position 92 of the gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID586048Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type U1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID323837Antibacterial activity against fusidic acid resistant Clostridium difficile 49:3 isolate with fusA S116L and A374V mutation after 35 to 40 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID1566016Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival at 5 uM after 72 hrs by MTT assay (Rvb = 100.58 +/- 7.78%)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1532506Induction of apoptosis in human HeLa cells assessed as increase in ratio of sub-G0 to G1 phase at 5 uM after 48 to 72 hrs by propidium iodide staining based FACS analysis
AID520084Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID576362Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring H457Q mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID324710Antimicrobial activity against Staphylococcus aureus RN4220 expressing pAJ96:fusB2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID581656Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1415895Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation cou2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID576372Antibacterial activity against fusidic acid-resistant Staphylococcus aureus harboring R76C in domain 1 and H457Y mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID1887604Antibacterial activity against Staphylococcus aureus ATCC 29213 infected in Swiss mouse skin infection model assessed as reduction in skin bacterial load at 2 % dose administered twice daily for 4 days2022Journal of natural products, 10-28, Volume: 85, Issue:10
Developing the Natural Prenylflavone Artocarpin from
AID324720Antimicrobial activity against Staphylococcus saprophyticus ATCC 153052007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1474152AUC in patient with osteomyelitis at 1500 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID324692Antimicrobial activity against Staphylococcus aureus 649 expressing pUB1012007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID1532491Cytotoxicity against human HeLa cells assessed as cell viability at 5 uM after 72 hrs by MTT assay relative to control
AID586040Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID424347Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH199 harboring TAA stop codon at nucleotide 241 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID424830Antibacterial activity against kanamycin-resistant and fusidic acid-susceptible Staphylococcus aureus AH417 harboring -1 frameshift mutation at nucleotide 422 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561994Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27624 carrying pUB101 expressing cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID1532508Inhibition of protein synthesis in human HeLa cells assessed as decrease in puromycin-incorporated neo-synthesized proteins at 5 uM preincubated for 2 hrs followed by puromycin addition and measured after 10 mins by chemiluminescence assay
AID581659Fraction unbound in human plasma2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID571430Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method in presence of 2 ug/ml NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1460344Cytotoxicity against CHO cells2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents.
AID424593Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH379 (SCV-51) harboring TAA stop codon at nucleotide 418 in rplF but gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID561981Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28335 expressing FusC C90T mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID1322509Antibacterial activity against Staphylococcus aureus infected in BALB/c mouse model of superficial skin infection and biofilm formation assessed as reduction in bacterial load in skin at 40 mg/kg applied topically once daily for 4 days and measured 18 hrs
AID545939Ratio of MIC for Acinetobacter baumannii ATCC 19606 to MIC for Acinetobacter baumannii ATCC 19606 in presence of 4 ug/ml of NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1474154Ratio of drug concentration at steady state in patient with osteomyelitis at 1500 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID557091Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1532499Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID261275Antibacterial activity against Staphylococcus aureus CJ 2002006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID545936Ratio of MIC for Escherichia coli IH3080 to MIC for Escherichia coli IH3080 in presence of 4 ug/ml of NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID586045Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 1 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID1532502Cytotoxicity against human JHH7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1230064Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2272 assessed as inhibition of bacterial growth2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID561997Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus isolate 27980 carrying pUB101 expressing cadX coding sequence by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID571210Antibacterial activity against Pseudomonas aeruginosa ATCC 27853by Etest method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID571392Antibacterial activity against Acinetobacter baumannii ATCC 19606 by Etest method in presence of NAB7392008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID323840Antibacterial activity against fusidic acid resistant Clostridium difficile 57:1 isolate after 1 day2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile.
AID561984Antimicrobial activity against cadX coding sequence deficient Staphylococcus aureus isolate 28414 expressing FusC C90T mutant and harboring pMW2 by Etest2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
AID324688Antimicrobial activity against Staphylococcus aureus RN42202007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID545938Ratio of MIC for Enterobacter cloacae ATCC 23355 to MIC for Enterobacter cloacae ATCC 23355 in presence of 4 ug/ml of NAB7412010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID424338Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH196 harboring Pro406Leu mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID565482Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human plasma2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro bactericidal activity of iclaprim in human plasma.
AID1230065Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2372 assessed as inhibition of bacterial growth2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID1474153Drug concentration at steady state in patient with osteomyelitis at 1500 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID424339Antibacterial activity against fusidic acid-resistant Staphylococcus aureus AH198 harboring Gly452Ser mutation in fusA gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID477411Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID581657Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID324706Antimicrobial activity against Staphylococcus aureus RN4220 expressing pCU1 gene2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Genetic basis of resistance to fusidic acid in staphylococci.
AID586042Antimicrobial activity against Staphylococcus aureus clone 2-2 harboring staphylococcal cassette chromosome mec element type U3 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID261278Antibacterial activity against Staphylococcus epidermidis CK 52006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and biological evaluation of photoaffinity labeled fusidic acid analogues.
AID424588Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH348 (SCV-20) harboring TGA stop codon at nucleotide 244 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID285345Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus HT20041010 in Mueller-Hinton medium2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.
AID424604Antibacterial activity against kanamycin-resistant Staphylococcus aureus AH383 (SCV-55) harboring TAA stop codon at nucleotide 139 in rplF gene after 18 to 24 hrs by Etest strip assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Genetic and phenotypic identification of fusidic acid-resistant mutants with the small-colony-variant phenotype in Staphylococcus aureus.
AID576365Antibacterial activity against Staphylococcus aureus harboring L461S mutation in domain 3 of EF-G encoded by fusA gene after 16 to 20 hrs by CLSI agar dilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.
AID586044Antimicrobial activity against Staphylococcus aureus clone 3-3 harboring staphylococcal cassette chromosome mec element type 4 assessed as percent susceptible isolates by kirby-bauer method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1811Experimentally measured binding affinity data derived from PDB1995Journal of molecular biology, Dec-15, Volume: 254, Issue:5
Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1995Journal of molecular biology, Dec-15, Volume: 254, Issue:5
Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,691)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990768 (45.42)18.7374
1990's235 (13.90)18.2507
2000's292 (17.27)29.6817
2010's323 (19.10)24.3611
2020's73 (4.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 117.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index117.64 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index217.85 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (117.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (23.81%)5.53%
Trials117 (6.72%)5.53%
Reviews4 (19.05%)6.00%
Reviews100 (5.74%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies175 (10.05%)4.05%
Observational0 (0.00%)0.25%
Observational6 (0.34%)0.25%
Other12 (57.14%)84.16%
Other1,344 (77.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union [NCT01153828]1 participants (Actual)Observational2008-11-30Completed
Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study [NCT02123628]Phase 440 participants (Actual)Interventional2007-06-30Completed
A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial [NCT03052348]78 participants (Anticipated)Interventional2017-11-01Not yet recruiting
A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT02570490]Phase 3716 participants (Actual)Interventional2015-11-30Completed
Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema [NCT03395132]Phase 368 participants (Actual)Interventional2018-07-31Terminated(stopped due to Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial.)
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections [NCT00948142]Phase 2198 participants (Actual)Interventional2009-08-31Completed
Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children [NCT01113125]Phase 360 participants (Anticipated)Interventional2010-03-31Active, not recruiting
A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients [NCT00986856]Phase 458 participants (Actual)Interventional2004-05-31Terminated(stopped due to Enrollment failed)
A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. [NCT00718315]Phase 3201 participants (Actual)Interventional2009-04-30Completed
A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis [NCT05641298]Phase 20 participants (Actual)Interventional2023-02-10Withdrawn(stopped due to Corporate finances)
Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization: A Double-Blind Randomized Controlled Trial [NCT05353374]22 participants (Actual)Interventional2021-01-01Completed
[NCT01756924]Phase 214 participants (Actual)Interventional2012-12-31Terminated(stopped due to This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.)
The Healing Effects Of Honey and Hydrogel Products On The Diabetic Foot [NCT03816618]Early Phase 1120 participants (Actual)Interventional2020-01-01Completed
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated [NCT02569541]Phase 2/Phase 330 participants (Actual)Interventional2015-12-31Completed
The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial. [NCT03105505]Phase 475 participants (Anticipated)Interventional2017-04-28Enrolling by invitation
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053]63 participants (Actual)Interventional2018-02-08Terminated(stopped due to Results interim-analysis)
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679]Phase 4360 participants (Anticipated)Interventional2022-06-01Not yet recruiting
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections [NCT03378427]35 participants (Actual)Interventional2018-08-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00718315 (9) [back to overview]Percentage of Participants Who Develop Skin Rash
NCT00718315 (9) [back to overview]Percentage of Participants With Erythema
NCT00718315 (9) [back to overview]Percentage of Participants With Pain
NCT00718315 (9) [back to overview]Percentage of Participants With Pruritus
NCT00718315 (9) [back to overview]Time to Appearance of Skin Rash
NCT00718315 (9) [back to overview]Percentage of Participants With Erythema Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Pain Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Pruritus Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Skin Rash Stratified by Severity Grade
NCT00986856 (8) [back to overview]The Actual Change in Total Severity Score From Baseline to End of Treatment (LOCF).
NCT00986856 (8) [back to overview]Number of Patients With Bacteriological Success at EOT
NCT00986856 (8) [back to overview]Number of Patients With Bacteriological Success at Visit 2
NCT00986856 (8) [back to overview]Number of Patients With Bacteriological Success at Visit 3
NCT00986856 (8) [back to overview]Number of Patients With Clinical Success (Marked Improvement or Completely Cleared) and Bacteriological Success (Eradication) at End of Treatment (EOT).
NCT00986856 (8) [back to overview]Number of Patients With Clinical Success at EOT
NCT00986856 (8) [back to overview]Number of Patients With Clinical Success at Visit 2
NCT00986856 (8) [back to overview]Number of Patients With Clinical Success at Visit 3
NCT02569541 (8) [back to overview]Clinical Success at 12 Months
NCT02569541 (8) [back to overview]Clinical Success at 15 Months
NCT02569541 (8) [back to overview]Clinical Success at 18 Months
NCT02569541 (8) [back to overview]Clinical Success at 21 Months
NCT02569541 (8) [back to overview]Clinical Success at 24 Months
NCT02569541 (8) [back to overview]Clinical Success at 6 Months
NCT02569541 (8) [back to overview]Clinical Success at 9 Months
NCT02569541 (8) [back to overview]Safety and Tolerability

Percentage of Participants Who Develop Skin Rash

"Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line Rash/desquamation - short name rash)." (NCT00718315)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Fisiogel60.0
Stiemicyn69.2
Verutex73.1

[back to top]

Percentage of Participants With Erythema

Erythema is defined as redness of the skin or mucous membranes, caused by hyperemia of superficial capillaries (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel56.7
Stiemicyn56.7
Verutex43.3

[back to top]

Percentage of Participants With Pain

Pain is defined as an unpleasant feeling often caused by intense or damaging stimuli (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel16.4
Stiemicyn25.4
Verutex13.4

[back to top]

Percentage of Participants With Pruritus

Pruritus is defined as intense localized itching (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel36.1
Stiemicyn47.6
Verutex29.5

[back to top]

Time to Appearance of Skin Rash

Time to occurence of skin rash was calculated as the number of days from Day 0 until the first appearance of skin rash as defined by NCI-CTCAE (NCT00718315)
Timeframe: Days 0, 15, and 30

InterventionDays (Median)
Fisiogel16.0
Stiemicyn15.0
Verutex15.0

[back to top]

Percentage of Participants With Erythema Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel37.739.323.0000
Stiemicyn39.736.522.21.600
Verutex52.539.36.61.600

[back to top]

Percentage of Participants With Pain Stratified by Severity Grade

The severity of pain was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel82.011.54.91.600
Stiemicyn73.022.24.8000
Verutex85.26.66.61.600

[back to top]

Percentage of Participants With Pruritus Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel63.919.714.81.600
Stiemicyn52.431.714.31.600
Verutex70.524.63.31.600

[back to top]

Percentage of Participants With Skin Rash Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel29.821.149.1000
Stiemicyn25.018.356.7000
Verutex18.343.335.03.300

[back to top]

The Actual Change in Total Severity Score From Baseline to End of Treatment (LOCF).

Total Severity Score is the sum of scores for the following 5 signs: Pustules/infected bullae, erythema, infiltration/induration, erosions and crusting. Each sign is assessed using a 4-point scale: 0=absent, 1=mild, 2=moderate and 3=severe involvement. Minimum Total Severity score is 0, maximum score is 15. (NCT00986856)
Timeframe: EOT: Visit at day 25

InterventionUnits on a scale (Mean)
Fucidin® Cream-3.9
Fucidin® Cream Vehicle-1.2

[back to top]

Number of Patients With Bacteriological Success at EOT

(NCT00986856)
Timeframe: EOT: Visit at day 25

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream1716
Fucidin® Cream Vehicle112

[back to top]

Number of Patients With Bacteriological Success at Visit 2

(NCT00986856)
Timeframe: Visit 2: Day 4

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream627
Fucidin® Cream Vehicle013

[back to top]

Number of Patients With Bacteriological Success at Visit 3

(NCT00986856)
Timeframe: Visit 3: Day 11

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream1710
Fucidin® Cream Vehicle15

[back to top]

Number of Patients With Clinical Success (Marked Improvement or Completely Cleared) and Bacteriological Success (Eradication) at End of Treatment (EOT).

(NCT00986856)
Timeframe: EOT: Visit at Day 25

,
InterventionParticipants (Number)
Clinical and bacteriological successClinical and bacteriological failure
Fucidin® Cream1617
Fucidin® Cream Vehicle112

[back to top]

Number of Patients With Clinical Success at EOT

(NCT00986856)
Timeframe: EOT: Visit at day 25

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream2713
Fucidin® Cream Vehicle79

[back to top]

Number of Patients With Clinical Success at Visit 2

(NCT00986856)
Timeframe: Visit 2: Day 4

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream1822
Fucidin® Cream Vehicle214

[back to top]

Number of Patients With Clinical Success at Visit 3

(NCT00986856)
Timeframe: Visit 3: Day 11

,
InterventionParticipants (Number)
SuccessFailure
Fucidin® Cream277
Fucidin® Cream Vehicle73

[back to top]

Clinical Success at 12 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 12-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 12 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)10155

[back to top]

Clinical Success at 15 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 15-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 15 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)8175

[back to top]

Clinical Success at 18 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 18-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 18 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)8166

[back to top]

Clinical Success at 21 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 21-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 21 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)6177

[back to top]

Clinical Success at 24 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 24-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 24 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)7176

[back to top]

Clinical Success at 6 Months

"Number of participants in the intent to treat (ITT) analysis set who meet all the criteria for clinical success at the 6-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 6 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)1893

[back to top]

Clinical Success at 9 Months

"Number of participants in the ITT analysis set who meet all the criteria for clinical success at the 9-Month Visit.~Clinical success was defined to occur when subjects met all of the following criteria: 1) Subject was not hospitalized due to worsening of the study-qualifying orthopedic infection. 2) Subject did not undergo a definitive surgical procedure (such as amputation). 2) No additional antibiotics (after completion of companion antibiotics) are required for treatment of the orthopedic infection due to the inclusionary pathogen. 3) Wound is closed, or the open area decreased in size (L x W) and, if a skin graft was done, the graft remains viable without evidence of infection. 4) No purulent discharge from the surgical wound, or new or recurring sinus tract. 5) No worsening of redness, tenderness, or swelling at the primary infection site. 5) No bacteremia" (NCT02569541)
Timeframe: 9 months after start of treatment

InterventionParticipants (Count of Participants)
Clinical SuccessClinical FailureIndeterminate
CEM-102 (Sodium Fusidate)15114

[back to top]

Safety and Tolerability

"Number of participants with TEAEs, SAEs, deaths, and discontinuations due to AEs.~Treatment-emergent adverse events, defined as events with a start date on or after the initiation of study drug through 28 days after the last dose of study drug, are reported." (NCT02569541)
Timeframe: Entire study period - up to 24 months

InterventionParticipants (Count of Participants)
Treatment Emergent AE (TEAE)Severe TEAETEAE Related to Study DrugTEAE Leading to Study DiscontinuationTEAE Leading to Study Drug DiscontinuationTE Serious Adverse Event (SAE)TE SAE with outcome of deathTE SAE Related to Study DrugTE SAE Leading to Study DiscontinuationTE SAE Leading to Study Drug Discontinuation
CEM-102 (Sodium Fusidate)29127912150079

[back to top]